Welcome to our dedicated page for MINIMED GROUP news (Ticker: MMED), a resource for investors and traders seeking the latest updates and insights on MINIMED GROUP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MINIMED GROUP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MINIMED GROUP's position in the market.
MiniMed (Nasdaq: MMED) announced FDA clearance of MiniMed Flex™ on March 18, 2026, a screenless, smartphone‑controlled insulin pump about half the size of the 780G with a 300‑unit reservoir. The pump uses SmartGuard™ with Meal Detection™ and demonstrated 80% Time in Range in real‑world results.
Commercial launch will pair Flex with Simplera Sync™ and Abbott Instinct sensors, begin a select customer phase this spring, and expand broadly in summer. Eligible 780G users can upgrade via the MiniMed™ Forward Program for $0.
MiniMed (Nasdaq: MMED) closed its initial public offering, selling 28,000,000 shares at $20.00 per share and began Nasdaq trading on March 6, 2026. Net proceeds to MiniMed were approximately $538 million after underwriting discounts and expenses.
As of closing, Medtronic owns ~90.03% of MiniMed common stock. MiniMed intends to use part of the proceeds for general corporate purposes and used the remainder to repay intercompany debt owed to Medtronic.
MiniMed Group (Nasdaq: MMED) began trading March 6, 2026 on the Nasdaq Global Select Market following an oversubscribed IPO.
The offering was described as the second largest IPO in medtech history and positions MiniMed to operate as a standalone company, while supporting Medtronic (NYSE: MDT)'s capital-focus strategy amid geopolitical market uncertainty.
MiniMed (Nasdaq: MMED) began trading on the Nasdaq Global Select Market on March 6, 2026 following its initial public offering. Leadership, including CEO Que Dallara, rang the Nasdaq Opening Bell to mark the listing. A Form S-1 registration statement has been filed and declared effective by the SEC.
The company positions itself as a global diabetes management leader and the only provider of a fully integrated insulin delivery system with connected devices designed to work together.
MiniMed Group (proposed Nasdaq: MMED) launched its IPO roadshow on Feb 24, 2026, offering 28,000,000 shares with an expected price range of $25.00–$28.00 per share and a 30-day over-allotment option for 4,200,000 shares.
Upon completion Medtronic (NYSE: MDT) would retain approximately 90.03% ownership (or 88.70% if the over-allotment is exercised). Proceeds will fund general corporate purposes, repay intercompany debt, and provide additional consideration to Medtronic. A Form S-1 has been filed but is not yet effective.